Vijaya Diagnostics Centre IPO Investment Note

Vijaya

IPO
Last Updated: 2021-09-01T19:36:17+05:30

Vijaya Diagnostics is a fairly well known diagnostic brand in the Southern part of India. Vijaya is the largest diagnostic chain in South India and also the fastest growing chain. It offers end-to-end solutions for pathology and radiology testing. Unlike many of the diagnostic centres, that are B2B in their model, Vijaya has adopted a predominantly B2C approach. More than 90% of its revenues come from customers directly walking into one of their diagnostic centres for a test. In 2014, Vijaya had taken over Medinova and is looking to expand further through the inorganic route.

Vijaya Diagnostics IPO is tapping the primary market with an IPO of Rs.1,895 crore consisting entirely of an offer for sale (OFS). The IPO has been priced in the band of Rs.522-531.

Key terms of the Vijaya Diagnostics IPO offer

Key IPO Details

Particulars

Key IPO Dates

Particulars

Nature of issue

Book Building

Issue Opens on

01-Sep-2021

Face value of share

Rs.1 per share

Issue Closes on

03-Sep-2021

IPO Price Band

Rs.522 - Rs.531

Basis of Allotment date

08-Sep-2021

Market Lot

28 shares

Refund Initiation date

09-Sep-2021

Retail Investment limit

13 Lots (364 shares)

Credit to Demat

13-Sep-2021

Retail limit - Value

Rs.193,284

IPO Listing date

14-Sep-2021

Fresh Issue Size

Nil

Pre issue promoter stake

59.78%

Offer for Sale Size

Rs.1,895 crore

Post issue promoters

54.78%

Total IPO Size

Rs.1,895 crore

Indicative valuation

Rs.5,414 crore

Listing on

BSE, NSE

HNI Quota

15%

QIB Quota

50%

Retail Quota

35%

Data Source: IPO Filings

Check out highlights of Vijaya Diagnostics business model

1.   Offers over 740 routine tests and over 870 specialized pathology tests
2.   Gets 95% of its revenues from states of Telangana and Andhra Pradesh
3.   Operates through a network of 80 diagnostic centres and 11 reference laboratories
4.   Smart growth in net profits and ROCE over the last 3 financial years
5.   Promoter Surendranath Reddy, Karakoram Fund and Kedaara will offer in the OFS
6.   Company has a 40 year pedigree having been established way back in 1981

 

Important Financials of Vijaya Diagnostics

Vijaya diagnostics is a profit-making company with consistent growth in top-line revenues, bottom-line net profits and return on capital employed. EBITDA  has grown 50% in the last 2 financial years.

 

Financial Parameter

Fiscal 2020-21

Fiscal 2019-20

Fiscal 2018-19

Net Worth

Rs.359.23 cr

Rs.274.14 cr

Rs.207.01 cr

Revenues

Rs.376.75 cr

Rs.338.82 cr

Rs.292.59 cr

EBITDA

Rs.177.88 cr

Rs.147.98 cr

Rs.118.48 cr

Net Profit

Rs.84.91 cr

Rs.62.51 cr

Rs.46.27 cr

Net Margins (%)

22.54%

18.45%

15.81%

ROCE (%)

42.01%

33.28%

30.06%

Data Source: Company RHP

The sharp growth in the net margins is a corollary to net profits growing much faster than growth in sales. From a shareholder perspective, what is material is the sharp increase in ROCE from 30.06% to 42.01%. This has been achieved through best in class operating revenue per customer at Rs.1,214 and operating revenue per test at Rs.428. These numbers have been benchmarked with competition by a CRISIL report.

How do the financials of Vijaya Diagnostics compare with the peer group? The CAGR growth in patient volumes between 2017 and 2021 for Vijaya was 14%, compared to 13% for Dr. Lal Pathlabs and Metropolis and 10% for Thyrocare. Vijaya has tests per patient at 2.7X compared to 2.4X for Dr. Lal Pathlabs, 2.1X for SRL and 1.9X for Metropolis. Vijaya has managed better customer penetration, especially in the particular geography.

Investment Perspective for Vijaya Diagnostics

Diagnostic testing is a fast growing business and the need to undergo regular check-ups was highlighted by the pandemic. Most of the listed diagnostic laboratories like Dr. Lal Pathlabs, Metropolis and Thyrocare have seen positive re-rating post the pandemic.

Here are key pointers for an investment view on the IPO.

  a)    Vijaya Diagnostics has the highest ratio of B2C to B2B at 93:7. This compares favourably with 23:77 for Thyrocare, 44:56 for Metropolis and 60:40 for Dr. Lal Pathlabs. Higher B2C business indicates higher level of customer brand recall and better retention.

  b)    Let us compare Vijaya Diagnostics with the peer group on operating revenues and operating profits per test. Vijaya ranks second after Metropolis in operating revenue per test and ranks on top in operating profit per test.

  c)    In terms of operating income and operating profit per patient, Vijaya Diagnostics scores substantially higher than peer group due to its strong B2C focus, which results in better customer penetration.

  d)    If you compare it's P/E ratio based on indicative post-issue valuations, it discounts profits at a P/E ratio of a little over 60X. That is still lower compared to 74X for Metropolis and 107X for Dr. Lal Pathlabs based on FY21 earnings. 

Vijaya Diagnostics offers an established story to participate in the fast growing diagnostic demand in India. In a competitive industry, Vijaya has got its profit per customer model right.
 

Start Investing in 5 mins*

Get Benefits worth 2100* | Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Open Free Demat Account

& get benefits worth 2100*

 
Resend OTP
Please Enter OTP
  • Have Promo code?
  • Use code ACT2100
Enter Promo code

By proceeding, you agree to the T&C.

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number